This article is more than 5 years old. Information may no longer be current.

Pexa-Vec trial for liver cancer ends after ‘disappointing’ interim results

SillaJen announced the discontinuation of a phase 3 trial designed to evaluate Pexa-Vec for the treatment of advanced liver cancer after interim analysis by the company’s independent data monitoring committee, according to a press release.

“The interim results are a disappointment to the company,” Eun Sang Moon, MD, CEO of SillaJen, stated in the release. “However, SillaJen has shifted its focus toward other combination therapies that offer a more compelling and commercially viable solution to address unmet needs in liver cancer as well as other therapeutic areas.

“Other programs have continued to deliver encouraging results,” Moon continued. “The discontinuation of the study will allow us to focus on a more promising development program.”

The trial comprised 600 patients who received Pexa-Vec followed by Nexavar (sorafenib, Bayer) or sorafenib alone.

While Pexa-Vec was generally well-tolerated by patients, interim results revealed that the study was unlikely to meet the primary endpoint of overall survival.

Reference: www.sillajen.com